Study Summary
This multicenter phase 1 trial with "3 + 3" dose escalation design seeks to examine the feasibility and safety of the administration of autologous T cells that have been modified through the introduction of chimeric antigen receptors targeting the B cell surface antigens CD19/20/22 following administration of a chemotherapy lymphodepletion regimen in adults with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) or Non-Hodgkin's lymphoma (NHL). The overall goals of this study are to estimate maximum tolerated dose (MTD) level, establish the overall safety profile and evaluate initial efficacy of administering duo-CAR-T cell treatment in this patient population.
Want to learn more about this trial?
Request More InfoInterventions
DuoCAR20.19.22-D95DRUG
Patient derived autologous T cells, lentiviral transduced to generate, using the Miltenyi CliniMACS Prodigy® closed transduction system, a Duo-CAR-T cells targeting cell surface antigens CD19/20/22.
Fludarabine (Conditional therapy)DRUG
Lymphodepletion chemotherapy
Cyclophosphamide (Conditional therapy)DRUG
Lymphodepletion chemotherapy
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| University of Kansas Cancer Center | Westwood | Kansas | United States |